Short answer
OptimizeRx Corp (OPRX) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition). $35.0M senior secured facilities: $25.0M term loan plus $10.0M revolver.
OptimizeRx Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $35.0M senior secured facilities: $25.0M term loan plus $10.0M revolver
- Refinanced Blue Torch term loan, funded working capital, and permitted stock repurchases
- Maturity extends to May 7, 2031, with quarterly term-loan amortization of $312,500
- Interest margins range from 1.75%–2.50% for Term SOFR loans and 0.75%–1.50% for Base Rate loans
- Financial covenants include minimum 1.20x fixed-charge coverage and maximum 2.75x net leverage, constraining future borrowing and distributions
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Results press release issued May 12, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OptimizeRx Corp 8-K filings
Get the next OPRX 8-K as it lands
Follow OPRX for push alerts, or ask the research agent what this filing means.